ECE2010 Poster Presentations Adrenal (66 abstracts)
1DMCS, Internal Medicine 4, University of Padova, Padova, Italy; 2Internal Medicine and Public Health, University of LAquila, LAquila, Italy; 3Internal Medicine, University of Rome, Rome, Italy; 4Endocrinology, University of Turin, Turin, Italy; 5Internal Medicine, University of Milan, Milan, Italy; 6Internal Medicine, Legnano, Italy; 7Endocrinology, University of Padova, Padova, Italy.
The screening for primary aldosteronism (PA) is based on the aldosterone/renin ratio (ARR), which is calculated with the plasma renin activity (PRA) as denominator. A direct measurement of active renin (DRA) is being used as an alternative to PRA, but its diagnostic performance remains uncertain.
Aim of the study was to head-to-head compare the ARR based on PRA (ARR-P) to on DRA (ARR-D), at baseline and post-captopril, for identifying aldosterone-producing adenoma (APA) in a subset (251 patients) of the PAPY Study.
The area (AUC) under the ROC curves was employed for estimating the accuracy of ARR-D and ARR-P for identifying APA and for between tests comparison. PA was found in 13.2% patients, 6.4% of whom had APA and 6.8% idiopathic hyperaldosteronism (IHA); 218 (86.8%) had primary hypertension. The PRA and the DRA showed a weaker correlation at baseline (r=0.26, P<0.0001) and a stronger post-captopril (r=0.65, <0.0001). Both the ARR-D and the ARR-P were useful for identifying APA, as shown by AUC under the ROC curves (0.870±0.058 and 0.973±0.028, respectively) >0.50 (both P<0.0001); at a between-test comparison the ARRs did not differ significantly. For the ARR-D the optimal cut-off value for identifying APA was 27.3, remarkably similar to that previously determined for the ARR-P. Thus, the ARR-D represents a reasonable alternative to the ARR-P for detecting APA.